Tags

Type your tag names separated by a space and hit enter

Pharmacological treatment of obesity.
Arq Bras Endocrinol Metabol. 2006 Apr; 50(2):377-89.AB

Abstract

This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant.

Authors+Show Affiliations

Endocrinology and Metabology Division, Hospital das Clínicas, Medical School, University of São Paulo, São Paulo, SP. mmancini@usp.brNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16767304

Citation

Mancini, Marcio C., and Alfredo Halpern. "Pharmacological Treatment of Obesity." Arquivos Brasileiros De Endocrinologia E Metabologia, vol. 50, no. 2, 2006, pp. 377-89.
Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metabol. 2006;50(2):377-89.
Mancini, M. C., & Halpern, A. (2006). Pharmacological treatment of obesity. Arquivos Brasileiros De Endocrinologia E Metabologia, 50(2), 377-89.
Mancini MC, Halpern A. Pharmacological Treatment of Obesity. Arq Bras Endocrinol Metabol. 2006;50(2):377-89. PubMed PMID: 16767304.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacological treatment of obesity. AU - Mancini,Marcio C, AU - Halpern,Alfredo, Y1 - 2006/05/23/ PY - 2006/6/13/pubmed PY - 2007/3/9/medline PY - 2006/6/13/entrez SP - 377 EP - 89 JF - Arquivos brasileiros de endocrinologia e metabologia JO - Arq Bras Endocrinol Metabol VL - 50 IS - 2 N2 - This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant. SN - 0004-2730 UR - https://www.unboundmedicine.com/medline/citation/16767304/Pharmacological_treatment_of_obesity_ L2 - http://www.diseaseinfosearch.org/result/9028 DB - PRIME DP - Unbound Medicine ER -